Analysis of single nucleotide polymorphisms associated with the vitamin D pathway in the placentas of women with gestational diabetes mellitus: a laboratory study

Article information

J Yeungnam Med Sci. 2023;40(Suppl):S9-S16

Publication date (electronic) : 2023 May 8

doi : https://doi.org/10.12701/jyms.2023.00150

Mi Ju Kim, Hyun Mi Kim, Hyun-Hwa Cha, Won Joon Seong

Department of Obstetrics and Gynecology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea

Corresponding author: Won Joon Seong, MD, PhD Department of Obstetrics and Gynecology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea Tel: +82-53-200-5724 • Fax: +82-53-423-7905 • E-mail: wjseong@knu.ac.kr

Received 2023 February 8; Revised 2023 March 24; Accepted 2023 March 28.

Abstract

Introduction

Gestational diabetes mellitus (GDM) affects 1% to 14% of all pregnancies [1] and is defined as a state of glucose intolerance that occurs during pregnancy [2]. Recently, GDM has become more common due to advanced maternal age, obesity, and multiple pregnancies from the use of assisted reproductive techniques [3,4]. The occurrence of GDM and the genetic background of the patient are known to be associated because there is often a family history of GDM, and recurrence of GDM is common in subsequent pregnancies [4].

Several factors play a role in the occurrence of GDM, and GDM has been linked to vitamin D deficiency [5]. Vitamin D is an important factor in bone metabolism and is known to cause pregnancy-related complications because of its role in pregnancy maintenance. The concentration of vitamin D in maternal blood increases throughout pregnancy, reaching approximately twice the prepregnancy concentration in the third trimester [6-8]. Moreover, the placenta regulates the expression of enzymes involved in vitamin D metabolism and the concentration of vitamin D is elevated by CYP2B1 expression, and downregulation of CYP24A1 and group-specific component, the latter of which is the main protein responsible for the transport of active vitamin D [9]. Examining the genetic variations in vitamin D pathway-regulating genes present in the placental tissue of mothers with GDM will also help us understand the genetic background of GDM.

Single nucleotide polymorphisms (SNPs) are site-specific genome variants in which one nucleotide base is replaced with another [10]. Polymorphisms refer to mutations that occur in more than 1% of the population, while those occurring in less than 1% of the population are called mutations [11]. SNPs are the most common genetic variants and are widely used as markers for genetic mapping because of their low variability and high intergenerational stability [12,13].

Therefore, this study analyzed the SNPs of genes known to be involved in vitamin D metabolism in the placenta using the placental tissue of mothers diagnosed with GDM to determine whether specific SNPs and the occurrence of GDM are related.

Methods

1. Participants and tissue sampling

We enrolled 40 women with GDM and 40 women without GDM of the same gestational age as the control group. GDM was diagnosed using a two-step approach: a 50-g glucose tolerance test as a screening test between 24 and 28 weeks of gestation and a 100-g glucose tolerance test when the initial test value was greater than 140 mg/dL. In addition, the Carpenter–Coustan criteria were used to diagnose GDM [14]. All women delivered at full term and had no fetal chromosomal or structural anomalies. Women with pregnancy-related complications or risk factors, such as multiple pregnancies, gestational hypertension, preeclampsia, preterm labor, and fetal growth restriction, were excluded from this study (Fig. 1). Maternal blood was drawn from a cannulated vein during the first trimester of pregnancy and before delivery, and 25-hydroxyvitamin D (25(OH)D) levels were determined using a commercial enzyme immunoassay kit. A level of 25(OH)D <20 mg/dL was defined as vitamin D deficiency [15,16]. For all 80 participants, the placenta was cut into 1×1-cm pieces and stored in a freezer at –70°C immediately after delivery.

Fig. 1.

Patient flow diagram in this study. All women deliver at full term with no fetal chromosomal or structural anomalies. If a woman has pregnancy-related complications and risks, such as multiple pregnancies, gestational hypertension, preeclampsia, preterm labor, or fetal growth restrictions, she is excluded from the study. VITD, vitamin D; GDM, gestational diabetes mellitus; IUGR, intrauterine growth restriction.

3. DNA extraction and genotyping

The QIAamp Fast DNA Tissue Kit (Qiagen, Valencia, CA, USA) was used to extract genomic DNA from the postoperative placental tissue, and the quality and quantity of the extracted DNA were evaluated using a NanoDrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) [17].

SNP genotyping was performed on an Applied Biosystems 7500 real-time polymerase chain reaction (PCR) system (Applied Biosystems, Foster City, CA, USA) using rhAmp SNP Assays (Integrated DNA Technologies, Coralville, IA, USA) and TaqMan SNP Genotyping Assays (Applied Biosystems). Table 1 lists the predesigned assays.

Table 1.

Predesigned rhAmp SNP Assays and TaqMan SNP Genotyping Assays

The rhAmp SNP Genotyping Assay was performed in accordance with the manufacturer’s instructions. The 10-μL PCR mix included 5 ng of DNA, 5.3 μL of Combined Master Mix and Reporter Mix, 2× rhAmp Genotyping Master Mix (Integrated DNA Technologies), 40× rhAmp Reporter Mix with Reference (Integrated DNA Technology), and 0.5 μL of rhAmp SNP assays (Integrated DNA Technologies). The PCR cycling was performed according to the manufacturer’s recommendation (60°C for 1 minute, 95°C for 10 minutes, followed by 40 cycles of 95°C for 10 seconds, 60°C for 30 seconds, and 68°C for 20 seconds).

The TaqMan SNP Genotyping Assay was performed following the manufacturer’s instructions. The 10-μL PCR mix comprised 10 ng of genomic DNA, 5.0 μL of 2× TaqMan Universal PCR Master Mix No UNG, and 0.5 μL of 20× SNP Genotyping Assay (probes and primers). The PCR cycling was performed according to the manufacturer’s recommendation (60°C for 1 minute, 95°C for 10 minutes, followed by 40 cycles of 92°C for 15 seconds and 60°C for 60 seconds).

Using the chi-square tests, the genotype frequencies of the given data were examined for compliance with the Hardy–Weinberg equilibrium.

Results

Table 2 summarizes the baseline characteristics of patients in the GDM and control groups. There were no significant differences between the two groups in terms of gestational age at delivery, birth weight, or placental weight. However, the maternal age, prepregnancy maternal weight, and body mass index (BMI) were higher in the GDM group than in the control group. At the time of delivery, vitamin D levels were lower (21.05±12.05 mg/dL vs. 31.31±20.72 mg/dL, p=0.012) and the frequency of vitamin D deficiency was higher (60.7% vs. 32.5%, p=0.040) in the GDM group than in the control group. To determine whether significant differences in maternal age and prepregnancy BMI between the GDM and control groups affected vitamin D levels, these confounding factors were corrected and analyzed. The results also confirmed that vitamin D levels in the GDM group were lower than those in the control group.

Table 2.

Basal characteristics of the GDM and control groups

All observed allele and genotype frequencies were in Hardy–Weinberg equilibrium. Table 3 shows that there was no statistically significant difference in the allele frequencies of all SNPs except for rs10877012. In women with GDM, the G allele of rs10877012 was more common (86.3% vs. 65.0%, p=0.002). In addition, the allele frequency of rs2248359 showed borderline significance (p=0.051). Table 4 shows the genotype frequencies of the SNPs. Among the seven SNPs studied, rs10877012 revealed the most significant difference, with the rs10877012 GG genotype being more common in the GDM group (72.5% vs. 42.5%, p=0.007) and the rs10877012 TT genotype being more common in the control group (0% vs. 12.5%, p=0.007). Although not statistically significant, the rs6013897 TT genotype was less common in the GDM group (p=0.051).

Table 3.

Allele frequencies at Hardy–Weinberg equilibrium of SNPs

Table 4.

Genotype frequencies of SNPs

Discussion

Vitamin D is a steroid hormone responsible for the metabolism of calcium and phosphorus and is associated with bone mineralization; however, it is also linked to the pathogenesis of various diseases. In particular, it has been reported to be closely related to cardiovascular disease [19], cancerous conditions such as colorectal cancer [20], obesity [15], and autoimmunity [21]. In the field of obstetrics, vitamin D is associated with preterm birth [22] and preeclampsia [23,24]. In addition, it acts on beta cells, affecting GDM occurrence [25], implying that genetic variation in the vitamin D pathway is a major risk factor for GDM.

In general, vitamin D concentration is regulated by the activity of enzymes found in the kidneys. 1-Hydroxylase (i.e., CYP27B1) converts 25(OH)D into 1,25-dihydroxyvitamin D (1,25(OH)2D), an active form with biological functions, whereas 24-hydroxylase (i.e., CYP24A1) catabolizes 25(OH)D and 1,25(OH)2D into inactive forms. 25(OH)D is the main circulating metabolite of vitamin D and is an indicator of vitamin D concentration [15]. During pregnancy, 1-hydroxylase, 24-hydroxylase, vitamin D receptor, and vitamin D-binding protein are found in the placenta, indicating that the placenta is closely involved in vitamin D metabolism [24,26,27].

In this study, mothers with GDM had lower serum vitamin D concentrations before delivery and a higher incidence of vitamin D deficiency than those in the control group. The GDM group was older than the control group and had a higher BMI before pregnancy. However, after correcting for confounding factors, the GDM group also had lower vitamin D levels. Agüero-Domenech et al. [28] reported in 2021 on the relationship between vitamin D, GDM, and BMI, indicating that vitamin D levels and BMI were not significantly related in patients with GDM. In the present study, there was no statistically significant difference between the GDM and control groups with respect to vitamin D supplementation. Vitamin D levels were not significantly different in the two groups in the first trimester of pregnancy but were significantly different just before delivery. Thus, vitamin D may have a certain effect on GDM pathogenesis and metabolism.

Consistent with this study, several papers have already reported that GDM and vitamin D deficiency measured in the third trimester of pregnancy are closely related [16,29,30]. A previous study showed that lower vitamin D levels measured at 16 weeks of gestation increased the risk of future GDM [29]; however, another study found no link between vitamin D deficiency and GDM in the first trimester of pregnancy [31]. In the present study, vitamin D concentration in the first trimester of pregnancy was slightly higher in the GDM group than in the control group; however, the difference was not statistically significant, confirming the above findings. Vitamin D is produced in the placenta during pregnancy, and its concentration increases as the placental mass increases [16,32]. It can be seen that the association between GDM and vitamin D levels differs depending on the stage of pregnancy.

Cho et al. [16] reported an increase in the expression of CYP24A1, which is involved in the vitamin D pathway, in the placentas of mothers with GDM and found a link between its expression and blood vitamin D levels. Zhou et al. [33] studied the association between GDM occurrence and vitamin D receptor gene polymorphisms. In the present study, no statistically significance difference in CYP24A1 coding SNPs was found, but the difference between SNPs encoding the CYP27B1 gene was confirmed. In women with GDM, the rs10877012 G allele was the most common. Furthermore, the rs10877012 GG genotype was more common in the GDM group, whereas the rs10877012 TT genotype was more common in the control group. CYP27B1 is located on 12q14.1 and is composed of nine exons [20]. The rs10877012 is located in the CYP27B1 promoter, plays an important role in transcription and translation, and is related to the concentration of circulating 25(OH)D [34]. According to the SNP database, the MAF was found to be 27.8% in the global population, 35.0% in the control group, and 13.75% in the GDM group in this study.

The CYP27B1 gene polymorphism rs10877012 is associated with the development and prognosis of various diseases such as colorectal cancer, asthma, and chronic hepatitis C [20,35,36]. Moreover, a recent meta-analysis suggested that this CTP27B1 gene polymorphism is related to susceptibility to organ-specific autoimmune endocrine diseases [37]. Several studies have attempted to determine the correlation between type 1 diabetes mellitus (not GDM) and CYP27B1 gene polymorphisms but have not obtained consistent results [38-40].

The strength of the present study is that, to the best of our knowledge, it is the first to show a link between the CYP27B1 rs10877012 polymorphism and the occurrence of GDM, and the first to compare vitamin D levels in the first trimester of pregnancy and just before delivery in GDM and control groups. However, a limitation of this study is the small sample size. Both rs2248359 and rs6013897 polymorphisms showed borderline significance, emphasizing the need for further large-sample studies. GDM is caused by a complex mechanism and combination of various factors. In this study, a CYP27B1 gene polymorphism involved in the vitamin D pathway was identified, and its association with gestational diabetes was considered. We do not think that this one factor is the only mechanism underlying the disease. Furthermore, a long-term follow-up study will be needed in the future, and it will be interesting to learn about the differences in SNPs between the two groups, especially when mothers with GDM develop overt diabetes mellitus in the future versus those who do not.

In summary, mothers with GDM have lower serum concentrations of vitamin D before delivery than healthy controls, and vitamin D deficiency is common. This may be due to polymorphisms in a gene involved in vitamin D metabolism in the placenta. The CYP27B1 polymorphism of the CYP27B1 gene rs10877012 can also be considered one of the various causes of GDM pathogenesis.

Article information Continued